Literature DB >> 33535978

Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.

Rui Zhang1, Qi Li1, Jialu Fu1, Zhechuan Jin1, Jingbo Su1, Jian Zhang1, Chen Chen1, Zhimin Geng2, Dong Zhang3.   

Abstract

BACKGROUND: Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal malignancy of the biliary tract. Analysis of somatic mutational profiling can reveal new prognostic markers and actionable treatment targets. In this study, we explored the utility of genomic mutation signature and tumor mutation burden (TMB) in predicting prognosis in iCCA patients.
METHODS: Whole-exome sequencing and corresponding clinical data were collected from the ICGC portal and cBioPortal database to detect the prognostic mutated genes and determine TMB values. To identify the hub prognostic mutant signature, we used Cox regression and Lasso feature selection. Mutation-related signature (MRS) was constructed using multivariate Cox regression. The predictive performances of MRS and TMB were assessed using Kaplan-Meier (KM) analysis and receiver operating characteristic (ROC). We performed a functional enrichment pathway analysis using gene set enrichment analysis (GSEA) for mutated genes. Based on the MRS, TMB, and the TNM stage, a nomogram was constructed to visualize prognosis in iCCA patients.
RESULTS: The mutation landscape illustrated distributions of mutation frequencies and types in iCCA, and generated a list of most frequently mutated genes (such as Tp53, KRAS, ARID1A, and IDH1). Thirty-two mutated genes associated with overall survival (OS) were identified in iCCA patients. We obtained a six-gene signature using the Lasso and Cox method. AUCs for the MRS in the prediction of 1-, 3-, and 5-year OS were 0.759, 0.732, and 0.728, respectively. Kaplan-Meier analysis showed a significant difference in prognosis for patients with iCCA having a high and low MRS score (P < 0.001). GSEA was used to show that several signaling pathways, including MAPK, PI3K-AKT, and proteoglycan, were involved in cancer. Conversely, survival analysis indicated that TMB was significantly associated with prognosis. GSEA indicated that samples with high MRS or TMB also showed an upregulated expression of pathways involved in tumor signaling and the immune response. Finally, the predictive nomogram (that included MRS, TMB, and the TNM stage) demonstrated satisfactory performance in predicting survival in patients with iCCA.
CONCLUSIONS: Mutation-related signature and TMB were associated with prognosis in patients with iCCA. Our study provides a valuable prognostic predictor for determining outcomes in patients with iCCA.

Entities:  

Keywords:  Genomic mutation signature; Intrahepatic cholangiocarcinoma; Nomogram; Prognostic biomarker; Tumor mutation burden

Mesh:

Substances:

Year:  2021        PMID: 33535978      PMCID: PMC7860034          DOI: 10.1186/s12885-021-07788-7

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  34 in total

1.  Genomic spectra of biliary tract cancer.

Authors:  Hiromi Nakamura; Yasuhito Arai; Yasushi Totoki; Tomoki Shirota; Asmaa Elzawahry; Mamoru Kato; Natsuko Hama; Fumie Hosoda; Tomoko Urushidate; Shoko Ohashi; Nobuyoshi Hiraoka; Hidenori Ojima; Kazuaki Shimada; Takuji Okusaka; Tomoo Kosuge; Shinichi Miyagawa; Tatsuhiro Shibata
Journal:  Nat Genet       Date:  2015-08-10       Impact factor: 38.330

Review 2.  Oncogenes and cancer.

Authors:  Carlo M Croce
Journal:  N Engl J Med       Date:  2008-01-31       Impact factor: 91.245

3.  Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.

Authors:  Apinya Jusakul; Ioana Cutcutache; Chern Han Yong; Jing Quan Lim; Mi Ni Huang; Nisha Padmanabhan; Vishwa Nellore; Sarinya Kongpetch; Alvin Wei Tian Ng; Ley Moy Ng; Su Pin Choo; Swe Swe Myint; Raynoo Thanan; Sanjanaa Nagarajan; Weng Khong Lim; Cedric Chuan Young Ng; Arnoud Boot; Mo Liu; Choon Kiat Ong; Vikneswari Rajasegaran; Stefanus Lie; Alvin Soon Tiong Lim; Tse Hui Lim; Jing Tan; Jia Liang Loh; John R McPherson; Narong Khuntikeo; Vajaraphongsa Bhudhisawasdi; Puangrat Yongvanit; Sopit Wongkham; Yasushi Totoki; Hiromi Nakamura; Yasuhito Arai; Satoshi Yamasaki; Pierce Kah-Hoe Chow; Alexander Yaw Fui Chung; London Lucien Peng Jin Ooi; Kiat Hon Lim; Simona Dima; Dan G Duda; Irinel Popescu; Philippe Broet; Sen-Yung Hsieh; Ming-Chin Yu; Aldo Scarpa; Jiaming Lai; Di-Xian Luo; André Lopes Carvalho; André Luiz Vettore; Hyungjin Rhee; Young Nyun Park; Ludmil B Alexandrov; Raluca Gordân; Steven G Rozen; Tatsuhiro Shibata; Chawalit Pairojkul; Bin Tean Teh; Patrick Tan
Journal:  Cancer Discov       Date:  2017-06-30       Impact factor: 39.397

4.  Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.

Authors:  Chirag Nepal; Colm J O'Rourke; Douglas V N P Oliveira; Andrzej Taranta; Steven Shema; Prson Gautam; Julien Calderaro; Andrew Barbour; Chiara Raggi; Krister Wennerberg; Xin W Wang; Anja Lautem; Lewis R Roberts; Jesper B Andersen
Journal:  Hepatology       Date:  2018-06-12       Impact factor: 17.425

5.  Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?

Authors:  Conor E Steuer; Suresh S Ramalingam
Journal:  J Clin Oncol       Date:  2018-01-16       Impact factor: 44.544

Review 6.  Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis.

Authors:  Michael N Mavros; Konstantinos P Economopoulos; Vangelis G Alexiou; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2014-06       Impact factor: 14.766

7.  Mutational landscape of intrahepatic cholangiocarcinoma.

Authors:  Shanshan Zou; Jiarui Li; Huabang Zhou; Christian Frech; Xiaolan Jiang; Jeffrey S C Chu; Xinyin Zhao; Yuqiong Li; Qiaomei Li; Hui Wang; Jingyi Hu; Guanyi Kong; Mengchao Wu; Chuanfan Ding; Nansheng Chen; Heping Hu
Journal:  Nat Commun       Date:  2014-12-15       Impact factor: 14.919

8.  Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy.

Authors:  Huayong Cai; Yu Zhang; Haoyun Zhang; Chao Cui; Chonghui Li; Shichun Lu
Journal:  J Surg Oncol       Date:  2020-01-29       Impact factor: 3.454

9.  Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection.

Authors:  Gaya Spolverato; Yuhree Kim; Sorin Alexandrescu; Hugo P Marques; Jorge Lamelas; Luca Aldrighetti; T Clark Gamblin; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Thuy B Tran; J Wallis Marsh; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2015-06-10       Impact factor: 5.344

10.  Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.

Authors:  Bingqi Ma; Huijuan Meng; Ye Tian; Yingying Wang; Tianqiang Song; Ti Zhang; Qiang Wu; Yunlong Cui; Huikai Li; Wei Zhang; Qiang Li
Journal:  BMC Cancer       Date:  2020-04-15       Impact factor: 4.638

View more
  4 in total

1.  High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma.

Authors:  Jian-Ping Song; Xue-Zhi Liu; Qian Chen; Yan-Feng Liu
Journal:  World J Clin Cases       Date:  2022-01-21       Impact factor: 1.337

Review 2.  ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms.

Authors:  Shankun Zhao; Youwen Xu; Weizhou Wu; Pan Wang; Yichao Wang; Hao Jiang; Jie Zhu
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

3.  Development and Validation of a Mutational Burden-Associated LncRNA Signature for Improving the Clinical Outcome of Hepatocellular Carcinoma.

Authors:  Mingjun Xu; Ting Ma; Shanping Shi; Jingjun Xing; Yang Xi
Journal:  Life (Basel)       Date:  2021-11-28

Review 4.  Current Advances in Basic and Translational Research of Cholangiocarcinoma.

Authors:  Keisaku Sato; Leonardo Baiocchi; Lindsey Kennedy; Wenjun Zhang; Burcin Ekser; Shannon Glaser; Heather Francis; Gianfranco Alpini
Journal:  Cancers (Basel)       Date:  2021-07-01       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.